𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reversible posterior leukoencephalopathy syndrome in a patient with multiple system atrophy: A possible association with oral midodrine treatment

✍ Scribed by Joong-Seok Kim; Kwang-Soo Lee; Sung-Chul Lim; Jae-Young Ahn; In-Uk Song; Yeong-In Kim; Bum-Soo Kim; Hee-Tae Kim

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
165 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We describe a 51‐year‐old man with a 3‐year history of multiple system atrophy, who developed a reversible posterior leukoencephalopathy syndrome (RPLS) after receiving prescription midodrine for therapeutic treatment of orthostatic hypotension. Typical reversible magnetic resonance imaging findings, following treatment with midodrine, suggested a possible relationship between midodrine treatment, supine hypertension, and RPLS, although a cause‐and‐effect relationship cannot be confirmed. © 2007 Movement Disorder Society

📜 SIMILAR VOLUMES

Reversible posterior leukoencephalopathy
Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia
✍ Bungo Saito; Tsuyoshi Nakamaki; Hidetoshi Nakashima; Takako Usui; Norimichi Hatt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract A 56‐year‐old man was admitted to our hospital with leukocytosis, anemia, and thrombocytopenia. Acute monoblastic leukemia was diagnosed. Two subsequent courses of consolidation chemotherapy consisted of conventional doses of cytarabine and intermediate‐dose cytarabine. Intermediate‐dos

Possible association between Budd-Chiari
Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
✍ Mevlüt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim Güllü; Emin Ka 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication